Cell Therapeutics Announces Removal of Partial Clinical Hold on Tosedostat
January 02, 2014 at 07:19 AM EST
Cell Therapeutics (NASDAQ: CTIC ) today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue. Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required